WO2003086334A1 - Produit tonique pour la pousse de cheveux - Google Patents
Produit tonique pour la pousse de cheveux Download PDFInfo
- Publication number
- WO2003086334A1 WO2003086334A1 PCT/JP2003/004884 JP0304884W WO03086334A1 WO 2003086334 A1 WO2003086334 A1 WO 2003086334A1 JP 0304884 W JP0304884 W JP 0304884W WO 03086334 A1 WO03086334 A1 WO 03086334A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- hair
- wnt
- hydrogen atom
- Prior art date
Links
- 230000003779 hair growth Effects 0.000 title claims abstract description 33
- 230000001256 tonic effect Effects 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 195
- 101150109862 WNT-5A gene Proteins 0.000 claims abstract description 72
- 210000004209 hair Anatomy 0.000 claims abstract description 68
- 230000010261 cell growth Effects 0.000 claims abstract description 17
- 239000007952 growth promoter Substances 0.000 claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 108020004999 messenger RNA Proteins 0.000 claims description 43
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 15
- 238000012216 screening Methods 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 125000000676 alkoxyimino group Chemical group 0.000 claims description 3
- 230000002934 lysing effect Effects 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 229940124563 hair growth stimulant Drugs 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 301
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 120
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 90
- 210000004027 cell Anatomy 0.000 description 84
- 230000002829 reductive effect Effects 0.000 description 78
- 239000000203 mixture Substances 0.000 description 62
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- 239000000243 solution Substances 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- 239000002609 medium Substances 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 34
- 230000002500 effect on skin Effects 0.000 description 34
- 210000003780 hair follicle Anatomy 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 210000003491 skin Anatomy 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- 238000010521 absorption reaction Methods 0.000 description 21
- 238000001514 detection method Methods 0.000 description 21
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 21
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 20
- -1 hydroxyimino group Chemical group 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 239000012046 mixed solvent Substances 0.000 description 19
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- 229960001866 silicon dioxide Drugs 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 229940126214 compound 3 Drugs 0.000 description 16
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 16
- 238000002953 preparative HPLC Methods 0.000 description 16
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 16
- 229930192524 radicicol Natural products 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 230000035755 proliferation Effects 0.000 description 15
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000001816 cooling Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 238000012746 preparative thin layer chromatography Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 201000004384 Alopecia Diseases 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 108050003627 Wnt Proteins 0.000 description 9
- 102000013814 Wnt Human genes 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 241000282693 Cercopithecidae Species 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 7
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 150000004688 heptahydrates Chemical class 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 241000754833 Pochonia chlamydosporia Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108050006400 Cyclin Proteins 0.000 description 4
- 241000282553 Macaca Species 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 4
- 102000043366 Wnt-5a Human genes 0.000 description 4
- 108700020483 Wnt-5a Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000031774 hair cycle Effects 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 3
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 3
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000005042 acyloxymethyl group Chemical group 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229940126545 compound 53 Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000006783 corn meal agar Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical class [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 2
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101710181403 Frizzled Proteins 0.000 description 2
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000885585 Homo sapiens Frizzled-5 Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241001002196 Pochonia Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 101000819472 Rattus norvegicus Frizzled-2 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000006877 oatmeal agar Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- 125000005923 1,2-dimethylpropyloxy group Chemical group 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000013371 Amietia angolensis Species 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100038736 Histone H3.3C Human genes 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101001031505 Homo sapiens Histone H3.3C Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000905985 Rotiferophthora Species 0.000 description 1
- 108091006503 SLC26A1 Proteins 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 241000082085 Verticillium <Phyllachorales> Species 0.000 description 1
- 230000031712 Wnt receptor signaling pathway, planar cell polarity pathway Effects 0.000 description 1
- 241001211763 Yukara Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- XYIPYISRNJUPBA-UHFFFAOYSA-N [3-(3'-methoxyspiro[adamantane-2,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC(C3)CC2C4)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 XYIPYISRNJUPBA-UHFFFAOYSA-N 0.000 description 1
- WGPAQYSVWYWZKT-UHFFFAOYSA-N [C].[Ra] Chemical compound [C].[Ra] WGPAQYSVWYWZKT-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 101150054900 gus gene Proteins 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 150000002641 lithium Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102200102378 rs387906638 Human genes 0.000 description 1
- JOPPJXPSNQPPOK-UHFFFAOYSA-N s-phenyl 2-chloroethanethioate Chemical compound ClCC(=O)SC1=CC=CC=C1 JOPPJXPSNQPPOK-UHFFFAOYSA-N 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005922 tert-pentoxy group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Definitions
- the present invention relates to a hair papilla cell growth promoter, a hair growth agent, and a hair restorer. More specifically, the present invention relates to a hair papilla cell growth promoter, a hair growth agent and a hair restorer containing a WNT-5A function inhibitor as an active ingredient. The present invention also relates to a method for screening a hair papilla cell growth promoter based on WNT-5A function inhibitory action. The end of the scenery
- Human hair follicles are composed of various epithelial and interdermal cells such as keratinocytes, dermal papilla cells, fibroblasts, and sebaceous cells.
- the hair growth cycle (hair cycle) is regulated.
- the body of the hair is formed by the proliferation of hair follicle keratinocytes, and controls the proliferation, differentiation and apoptosis of these hair follicle keratinocytes, and plays a central role in hair cycle regulation. Is responsible for the nipple. Therefore, it is important to study the effects on hair papilla cells in developing hair growth / growth agents.
- ⁇ T-15A is a secretory glycoprotein belonging to the Medical T family.
- the WNT family has about 20 types of molecules, each of which is widely conserved from nematodes to mammals. These WNTs are known to be important intercellular signal molecules that control fetal axis formation and organ formation (Aimu. Rev. Cell Dev. Biol. 14, 59-88 (1998), Genes & Dev. 11, 3286-3305 (1997)).
- the receptor for WNTs is a seven-transmembrane type Frizzled, and there are 10 types in humans (Aimu. Rev. Cell Dev. Biol.
- An object of the present invention is to provide a screening method using a molecule that controls the proliferation of hair papilla cells, a hair papilla cell growth promoter, and a hair growth or hair growth agent based on a novel action.
- a hair papilla cell growth promoter comprising a compound having a WNT-5A function inhibitory activity.
- a hair papilla cell proliferation promoter comprising a compound having an orchid T-5A production inhibitory action.
- R 1 and R 2 are the same or different and represent a hydrogen atom, an alkyl group or a C 2 _ 6 alkanoyl group,
- X represents a hydrogen atom or a halogen atom
- R 3 a and R 3 b represents a hydrogen atom or a hydroxyl or different
- R 4, R 5, R 6 , R 7, R 8 and R 9 are identical or different and represent a hydrogen atom, a hydroxyl group, or indicates a halogen atom or a C 2 _ 6 alkanoyloxymethyl noisy Ruo alkoxy group, or adjacent groups together To form a pi bond or an ether bond, or R 5 and R 8 or R 5 and R 9 together to form an ether bond.
- R 1 and R 2 are the same or different and represent a hydrogen atom, a 6 alkyl group or a C 2 _ 6 alkanoyl group,
- X represents a hydrogen atom or a Hagen atom
- R 3c ⁇ Pi R 3 ⁇ may be the same or different and represent a hydrogen atom, a hydroxyl group or a C t _ 6 alkoxy group to indicate carded or with R 3d are together a connexion Okiso group, a hydroxy I amino group or a C, _ 6 Arukokishii Forming a mino group,
- RRR 6, R 7, R 8 and R 9 are identical or different and represent a hydrogen atom, a hydroxyl group, halogen atom or a C 2 _ 6 alkanoyloxymethyl noisy Ruo xylene or a group, or adjacent groups Te summer together pi bond or R 5 and R 8 or R 5 together form an ether bond, or form an ether bond.
- a hair papilla cell growth promoter comprising the compound represented by the formula:
- R la and R 2a are the same or different and each represents a hydrogen atom, C t _ 6 alkyl groups, (: Bok 6 ⁇ Rukanoiru group, (CH 2 ) p CO-YR 10 (wherein, Y represents an oxygen atom or a sulfur atom, R 10 represents a hydrogen atom, an alkyl group or a substituted or unsubstituted aryl group, and P is 0 or 1 A) a group represented by
- R 11 is a substituted or unsubstituted cycloalkyl group or a substituted or unsubstituted C ⁇ , which represents a heterocyclic ring, and Q represents 0 or 1).
- a group represented by CO R 12 (wherein, R 12 represents a substituted or unsubstituted aryl group or a substituted or unsubstituted C 2 ; represents a heterocyclic ring),
- X represents a hydrogen atom or a halogen atom
- R 3e and R 3 f are the same or different and represent a hydrogen atom, a hydroxyl group, ⁇ it 6 alkoxy group or a C t _ 6 alkanoyloxymethyl noisy Ruo xylene or a group, or R 3e and R 3 f is together a connexion Okiso group, Forming a hydroxyimino group or _ 6 alkoxyimino group,
- R 4a , R 5a , R 6a , R 7 R 8a and R 9a are the same or different and are a hydrogen atom, a hydroxyl group, a halogen atom or
- ZR 13 (wherein, Z is an oxygen atom or a sulfur atom, R 13 is an alkyl group, Arukanoiru group or a substituted or unsubstituted Ariru group showing a.) Or indicate to a represented Ru group, or adjacent groups together a connexion or form a pi bond or an ether bond, or become R and R 8 a or R 5 a and R 9 a guard ⁇ to form an ether bond,
- R 6b represents a hydrogen atom or forms an ether bond together with R 3 e or R 3 f .
- a hair-growing agent or a hair-growing agent comprising the above-mentioned hair-papillary-cell proliferation-promoting agent as an active ingredient. I do.
- a method for screening for a hair papilla cell growth promoter which comprises selecting a substance that inhibits the function of WNT-5A.
- the present invention also provides a method for selecting a substance that inhibits the function of ⁇ T-15A, comprising the following steps (a) to (c): It is. 03 04884
- step (b) lysing the human ⁇ T-5A-expressing cells cultured in step (a), extracting RNA, and measuring the amount of WNT-5 ⁇ mRNA:
- step (c) a step of comparing the amount of WNT-5A mRNA measured in step (b).
- Fig. 1 shows an electrophoretogram showing that WNT-5A mRNA is expressed in dermal papilla cells.
- Fig. 2 shows that the test compound decreases the amount of WNT-5A mRNA in dermal papilla cells. The electropherogram is shown.
- FIG. 3 shows a graph showing that the test compound has a hair papilla cell growth promoting activity.
- FIG. 4 is an electrophoretogram showing reduction of WNT-5A mRNA in monkey skin organ culture.
- FIG. 5 shows the results of PCNA staining of telogen and anagen hair follicles in monkey skin organ culture.
- FIG. 6 presents a histogram showing that Compound 7 increases hair bulb diameter in monkey skin organ culture.
- FIG. 7 shows a histogram showing that compound 3 increases hair bulb diameter in monkey skin organ culture.
- Figure 8 shows enlarged photographs of the skin before and after application for 6 months in the macaque hair growth test
- a compound that inhibits the function of T-15A refers to a compound that inhibits the binding of T-15A to WNT-5A receptor. Or a compound that suppresses the production of WNT-5A, preferably the production of lightning T-5A 0304884 A compound that inhibits production.
- WNT-5A is a secreted glycoprotein belonging to the WNT family, whose expression has been confirmed in humans, mice, rats, African algae, etc., but it is human WNT-5A ( SEQ ID NO: 1) Compounds that inhibit function are preferred.
- a compound that inhibits the binding of WNT-15A to the TOT-5A receptor is defined as a compound that acts on the WNT-5A or WNT-5A receptor to temporarily bind the T15A to the T-15A receptor.
- Specific examples of the WNT-5A receptor include human Frizzled5 (SEQ ID NO: 4) and rat Frizzled2 (SEQ ID NO: 6).
- the compound may be peptidic or non-peptidic, but is preferably a non-peptidic inhibitor which has an advantage of a long action time.
- the compound can be selected by a screening system using labeled ⁇ T-15A and m-NT-5A receptors, and preferably has an IC 50 of 30 or less, more preferably 10 / M These are:
- the compound that suppresses 5A production means a compound that suppresses the expression of the WNT-5A gene.
- the compounds may be peptidic or non-peptidic, but non-peptidic inhibitors, which have the advantage of long action times, are preferred.
- the compound can be selected based on the decrease in the amount of WNT-5A protein (SEQ ID NO: 1) or the amount of WNT-5A mRNA (SEQ ID NO: 2), and is preferably determined by the method of Hartley et al. (Drug Metabolism). and Dis position 28 (5), 608-616 (2000), and the IC 5 E include: a nucleic acid pro one poor Ssi method according to test example 4) to be described later, hereinafter the well because more preferably 10 M is there.
- Formula (I), the _ 6 alkyl group in the compounds represented by (II) and (DO, means a straight or branched alkyl group of from 1 to 6 carbon atoms, specifically, for example, Examples include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, pentyl group, 2-ethylpropyl group, and hexyl group.
- the C 6 alkanol group means a linear or branched alkynyl group having 1 to 6 carbon atoms, specifically, for example, an acetyl group, a propionyl group, a butyryl group, a t-butylyl group and the like. Can be mentioned.
- ( ⁇ _ 6 alkoxy group means a linear or branched alkoxy group having 1 to 6 carbon atoms, specifically, for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group , Isobutoxy group, sec-butoxy group, tert-butoxy group, pentoxy group, isopentyloxy group, neopentyloxy group, tert-pentoxy group, 1-methylbutoxy group, 2-methylbutoxy group, Examples thereof include a 1,2-dimethylpropoxy group, a hexyloxy group, and an isohexyloxy group.
- the ci _ 6 Arukokishiimino group means a linear or branched alkoxy Shiimino group of from 1 to 6 carbon, specifically, for example, N- Metokishiimino group, N - Etokishiimi amino group, N- Examples include a propoxyimino group, an N-isopropoxyimino group, an N-butoxyimino group, an N-isobutoxyimino group, an N-pentyloxyimino group, and an N-hexyloxyimino group.
- alkanoyloxy group means a linear or branched alkanoyloxy group having 1 to 6 carbon atoms, specifically, for example, acetoxy group, propionyloxy group, pivaloyloxy group, etc. Is mentioned.
- the C 3 _ 1 Q cycloalkyl group means a cycloalkyl group having 3 to 10 carbon atoms, specifically, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl Group, cyclooctyl group, cyclononyl group and the like.
- cycloalkyl group examples include a halogen atom replacing the hydrogen atom of the cycloalkyl group, and substituted or unsubstituted C 1 .
- aryl groups include phenyl, naphthyl, and anthracene groups.
- TJP03 / 04884 Examples of the substituted aryl group include a halogen atom for the aryl group and a substituted or unsubstituted C 1 .
- Alkyl group a hydroxyl group, CH hydroxyalkyl group, Cal Bokishiru group, a mercapto group, an indazolyl group, an indolyl group, ( ⁇ - 5 alkylthio O group, Shiano group, a nitro group, an amino group, an amide group, Asechiruamino group and ⁇ Bok 5 alkoxy
- Aryl groups substituted with one or more groups selected from the group consisting of groups can be mentioned.
- heterocycles include furan, pyrrol, thiophene, oxazole
- Isooxazole thiazole, imidazole, pyrazole, pyran, pyridin, piperidine, pyridazine, pyrimidine, pyrazine, quinoline and the like.
- hetero ring examples include a hydrogen atom in the hetero ring, a halogen atom, and substituted or unsubstituted C 1 .
- Hetero rings substituted with one or more groups selected from the group consisting of 5 alkoxy groups can be mentioned.
- the ether bond one hundred and one, the formula - (C3 ⁇ 4) m - 0- ( CH 2) n - (wherein, m and n represents an integer of, respectively it 1-3, alkylene group in the formula is an alkyl . but it may also be substituted with a group) or the formula - 0- (CH 2) 0- (wherein, m represents an integer of 1 to 3, alkylene down group in the formula is substituted by an alkyl group May be used.)
- R 3e and R 6b are the same as above.
- R 3f and R 4a and (R and R Sa ) form a pi bond.
- compound 77) is preferable in that it effectively suppresses the expression of T-5A mRNA in dermal papilla cells and promotes the proliferation of dermal papilla cells.
- R la and R 2a represent (CH 2 ) p CO—Y—R 10 (wherein, Y represents an oxygen atom or a sulfur atom, and R lfl represents a hydrogen atom.
- (:. 6 shows an alkyl group or a substituted or unsubstituted ⁇ Li Ichiru group, p is indicating 0 or 1) is a group table in compounds (e.g., compound 52) or COR 12 (wherein And R 12 represents a substituted or unsubstituted aryl group or a substituted or unsubstituted heterocyclic ring.)
- compound 58 is a compound of WNT-5A mRNA in hair papilla cells. It is preferred in that it effectively suppresses expression and promotes proliferation of hair papilla cells.
- R 7a is Z-R 13 in group (wherein, Z is an oxygen atom or a sulfur atom, R 13 is showing a C 2 _ 6 Arukanoiru group or a substituted or unsubstituted Ariru group.) Represented by Certain compounds (eg, compound 53) are preferred because they effectively suppress the expression of WNT-5A mRNA in dermal papilla cells and promote the proliferation of dermal papilla cells.
- the compound represented by the formula (II) can be produced, for example, by combining the following production methods.
- R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and X are the same as defined above.
- An organic solvent eg, tetrahydrofuran, geethylether, ethyl alcohol
- a reducing agent such as sodium borohydride, lithium borohydride, and if necessary, salts such as LiCl, MgCl 2 , CeCI 3 , CaCl 2 , and NiCl , Methyl alcohol, etc.
- a compound of the formula (VI) is obtained by a commonly used separation method such as column chromatography Can be separated and purified.
- the compound of the formula (VIII) is obtained by treating the compound of the formula (VII) with an acid or a base in a suitable organic solvent (for example, tetrahydrofuran, getyl ether, ethyl alcohol, methyl alcohol and the like).
- a suitable organic solvent for example, tetrahydrofuran, getyl ether, ethyl alcohol, methyl alcohol and the like.
- the production of the compound (1, 60 to 78) represented by the formula (K) is carried out in a medium containing various nutrients in accordance with the production of general fermentation products.
- Chlamydosporia TF_0480te is cultured under favorable conditions (cultivated with Pochonia chlamydosporia var. Chlamydosporia TF_0480te).
- the medium is mainly a liquid medium and consists of a carbon source, a nitrogen source, and inorganic salts. If necessary, vitamins, precursors, and antifoaming agents can be added, and the pH is adjusted to around 7.
- a carbon source for example, glucose, dextrin, glycerin, starch and the like are used alone or in combination.
- the nitrogen source for example, meat extract, oatmeal, yeast extract, soybean powder, polypeptone, corn steep liquor, urea, ammonium salt and the like are used alone or in combination.
- the inorganic salt for example, monobasic phosphate, magnesium sulfate, sodium chloride, calcium carbonate or the like is used alone or in combination.
- Adekinol or a silicon compound can be used as the defoaming agent.
- Aerobic culture such as shaking culture and aeration and agitation culture is suitable for the culture method, and culture is performed at PH 4 to 10, 25 to 35 ° C for 2 to 5 days, and preferably at 25 to 28 ° C for 3 days.
- Isolation of 1,60 to 78 produced by this culture may be performed according to a general method for collecting fermentation products. For example, the following method is effective. That is, after completion of the culture, a culture filtrate is obtained by centrifugation or filtration, and is adsorbed on a polystyrene resin such as Diaion HP-20 (trade name, manufactured by Mitsubishi Chemical Corporation). Elute with solvent.
- the cells are extracted with an organic solvent such as lower alcohol or acetone. Then, the cell extract and the eluate from the adsorption resin are combined, concentrated under reduced pressure, and the remaining aqueous layer is extracted by adding an organic solvent such as ethyl acetate, black form, n-phenol, and the like. Is concentrated. The obtained residue is again Dissolved in organic solvents such as benzene, ethyl acetate, acetone, methanol, and gel-form, and used for silica gel column chromatography, gel filtration carm chromatography, and reverse-phase partitioning.
- the compound of the present invention can be purified and isolated by performing chromatography.
- the strain that produces the active ingredient of the present invention is a strain newly isolated from the soil by the present inventors, and has the microorganism name of ⁇ Poconia chlamydosporia variety Chlamydosporia TF-0480 (Pochonia chlamydosporia var.chlamydosporia TF-048).
- the colony formed by this strain on a cornmeal agar plate at 26 ° C for 14 days was observed with an optical microscope.
- the conidium-forming cells (phialides) were solitary directly on the mycelium or 2 to 4 cells formed in a ring form.
- the conidiophore was indistinguishable from the vegetative mycelium.
- Multiple conidia are formed at the tip of the fiaraid, and become a coamy.
- the phialide has a cylindrical shape with a tapered tip, a smooth surface, no color, a length of 13-35 ⁇ m, a thickness of 0.8-1.7 ⁇ m at the base, and 0.5-0.8m near the tip. Conidia are oval to rarely subglobular, often with a slightly protruding base.
- the surface is smooth, colorless and the size is 2.2-5.0X1.8-2.8 ⁇ m.
- pale yellow, multicellular, thick-membrane spores (dictiochlamidospores) having a reticulated septum at the tip of short stems generated from hyphae on the medium surface or on the medium.
- chlamydospores are also formed in the medium.
- the size of chlamydospores is 14-20X12-1 22 m. Even if the culture was extended for more than one month, no morphology of teleomorph was observed.
- This strain grows in the pH 6.0 sub-mouth liquid medium at a temperature of 15 to 31 ° C, and the optimal temperature is 25 to 27 ° C.
- This strain grows in YpSs liquid medium at 26 ° C in the range of ⁇ 3-10, and the optimum pH is 5-7.
- this strain was named "Poconia chlamydosporia variety Chlamydosporia TF-0480 (Pochonia chlamydosporia var. Chlamydosporia TF-0480) J.
- hair papilla cell growth promoter means a drug or a reagent having an action of increasing the number of hair papilla cells.
- the hair papilla cell growth promoter of the present invention is characterized in that it is based on the inhibitory action of WNT-5A function.
- WNT-5A activates the ⁇ T /) 3-catenin pathway. It suppresses the function of WNTs (l, 8, etc.) in the T-1 class.
- WNTs l, 8, etc.
- the proliferation of hair papilla cells is controlled. Therefore, even a compound having a completely different structure (for example, compound 24, compound 79, compound 7, etc.) has an excellent dermal papilla cell growth-promoting effect as long as it has an excellent WNT-5A function inhibitory effect. .
- Cell proliferation can be measured by a method known to those skilled in the art, and examples thereof include viable cell count using an appropriate chromogenic substrate, and [3H] -thymidine incorporation method.
- the color-developing substrate it is preferable to use tetrazolium salts such as MTT, MTS, XTT and the like, and Alamar Tablets.
- the “hair growth agent or hair restorer” is used for the purpose of inducing hair growth, promoting hair growth, preventing hair loss, and the like.
- the target of application includes, for example, improvement or prevention of alopecia areata and male pattern baldness.
- the effect of the hair-growing agent / hair-growth agent of the present invention is due to the effect of promoting the growth of the dermal papilla cells based on the suppression of WNT-5A function.
- This mechanism of action enhances the decreased cell proliferation ability of the hair loss dermal papilla, and forms a developed hair dermal papilla tissue. Is also expected to be effective.
- a synergistic effect can be expected by combination with a hair growth agent and a hair restorer having other action points.
- the hair growth agent and the hair growth agent of the present invention can be administered in various dosages and administration forms based on the respective compounds.
- the dose varies depending on the type of hair restorer and the form of administration.
- the compound represented by the formula ( ⁇ ) when applied by application (lotion, ointment, gel, etc.), 0.0001 to 10% by weight , Preferably 0.001 to 5% by weight, more preferably 0.001 to 1% by weight.
- the dose is preferably 1 to 100 mgZkgZ days.
- the mode of administration of the hair growth agent of the present invention z is not particularly limited.
- a T-5A production inhibitor such as a compound represented by the formula (IX) is effectively used.
- the hair growth agent to be used is provided in the form of a water-soluble composition.
- various additives humidityectants, thickeners, preservatives, oxidizing agents
- the hair growth agent Z of the present invention can be provided, for example, as a hair conditioning composition such as hair tonic, hair oil, hair mousse, or gel, or an ointment.
- a T-15A production inhibitor for example, a compound represented by the formula (IX)
- a suitable buffer such as purified water or a phosphate buffer.
- it is prepared as an emulsion and administered topically as a liquid formulation for the scalp.
- the liquid preparation may be applied directly to the scalp, or may be applied using an injection nozzle such as a spray.
- a WNT-5A production inhibitor for example, a compound represented by the formula (K) may be used as a fat, fatty oil, lanolin, petrolatum, paraffin, It can be topically administered as an external preparation for ointments and creams by mixing with plasters, resins, plastics, glycols, higher alcohols, glycerin, 7K, emulsifiers, suspending agents and the like.
- a WNT-15 production inhibitor for example, a compound represented by the formula (IX)
- a powder It may be used as an external preparation such as a powder or a solid preparation to be dissolved or suspended in a solvent before use and applied to the scalp.
- a pharmaceutically acceptable carrier excipient, binder, disintegrant, corrigent, etc.
- a T-5A production inhibitor such as a compound represented by the formula (K)
- Tablets, capsules, granules, powders, syrups and the like obtained by formulating a pharmaceutical composition obtained by blending with a diluent, a solubilizing agent, etc. according to a usual method. It is preferably provided in the form of a preparation, suspension, solution or the like.
- the present invention is also a method for screening for a hair papilla cell growth promoter, which comprises selecting a compound that inhibits the function of ⁇ T-5A.
- Selecting a compound that inhibits the function of WNT-5A means, for example, selecting a WNT-5A production inhibitor, ie, screening. You can also select the WNT-5A receptor antagonist.
- test substance used in the screening method of the present invention any substance can be used.
- the type of the test substance is not particularly limited, and may be an individual low molecular compound, a compound present in a natural product extract, or a synthetic peptide. Further, it may be a compound library or a combinatorial library. The construction of a compound library is known to those skilled in the art, and a commercially available compound library can also be used.
- the compound to be screened preferably has a molecular weight of 3000 or less from the viewpoint of use as a pharmaceutical, and is preferably a low molecular weight compound having a molecular weight of 600 or less from the viewpoint of enabling oral administration by application.
- a labeled ⁇ T-5A protein and tXWNT—5A receptor are used to detect or measure the label, thereby obtaining a ⁇ T-5A protein and a T-book.
- Labels include radioisotopes (32P, 33P, 1311, 1251, 3H, 14C, 35S, etc.), enzymes (alkaline phosphatase, horseradish peroxidase, etc.), fluorescence material
- an in vitro Atsey system is performed in a non-cellular system. Specifically, either the WNT-5A protein or the ⁇ T-15A receptor was bound to the support, the test substance was added to the other, and the mixture was incubated, washed, and bound to the support. What is necessary is just to detect or measure the binding of the other protein to the protein.
- the support to which the protein is bound includes, for example, insoluble polysaccharides, such as agarose, dextran, cellulose, synthetic resins, such as polystyrene, polyacrylamide, and silicon. More specifically, commercially available beads and plates manufactured using them as raw materials are used.
- the screening of the compound for inhibiting 5A production can be performed using the amount of WNT-5A mRNA or the amount of WNT-5A protein as an index.
- the expression level can also be detected by linking a reporter gene to the promoter region of the WNT-5A gene.
- SEQ ID NO: 3 is preferably used as the promoter of the WNT-5A gene.
- repo overnight gene examples include GFP gene (Green Fluorescent Protein), GUS gene (i3-Glucuronidase), LUC gene (Lucif erase), and CAT (Chloram phenicol acetyl trans ferase) gene.
- the ⁇ T one 5A mRNA amount as when an index, for example, using a human ⁇ T one 5A-expressing cells, the addition of the test substance, 37 ° C, 5% C0 2 - the number of the incubator 95% air Time After culturing, lyse the cells, extract the RNA, and measure the amount of T-15A mRNA using RT-PCR, etc., to search for a substance that has the activity to reduce the amount of T-15A mRNA. be able to.
- the primer used for PCR is not particularly limited as long as it is specific to WNT-5A mRNA, and it can be designed from the sequence of T_5A mRNA.
- it is preferably Forward Primer AATGTCTTCCAAGTTCTTCCTAGTGGC (SEQ ID NO: 8).
- Rev Primer GATGTCGGAATTGATACTGGCA SEQ ID NO: 9).
- the ⁇ T one 5A protein content as when an index, for example, using a human Wnt-5A-expressing cells, the addition of the test substance, 37 ° C, 5% C0 2 - several hours in an incubator of 95% air
- the protein is extracted using a culture medium or by lysing the cells, and the WNT-5A protein content is measured by ELISA (enzyme-1 inked immunosorbent assay) or the like. It is possible to search for a substance having an activity of reducing the expression level.
- ELISA enzyme-1 inked immunosorbent assay
- Example 16 (Compound 31) Radicicol (10.8 g) was dissolved in ethyl acetate (140 ml), 5% palladium on carbon (pet type) (255 mg) was added, the atmosphere was replaced with hydrogen (1 atm), and the mixture was stirred at room temperature for 3 hours. After the palladium carbon was filtered, the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography [Silica Gel 60 (trade name, manufactured by Merck)], and eluted with n-hexane: ethyl acetate (2: 1) to give compound 4 (3.43). Compound 3 (4. g) was obtained by eluting with n-hexane: ethyl acetate (3: 2).
- the obtained ethyl acetate layer was dried over anhydrous sodium sulfate, and the ethyl acetate was distilled off under reduced pressure to obtain a gum (1.46 g).
- a column of silica gel [Silica Gel 60 (trade name, manufactured by Merck)] prepared by dissolving the obtained substance in a mixed solvent of black mouth formumethanol (4: 1) and wetting with n-hexane. 400 ml).
- Fraction (1) was dissolved in a small amount of tetrahydrofuran, and preparative high-performance liquid chromatography using acetonitrile-water (pH 3.5, acetic acid) (35:65) mobile column [Column: YMC-Pack Pro C18 AS- 343 (20 X 250 mm), detection UV absorption 254 nm, flow rate lOml / min], collect three fractions, concentrate each fraction under reduced pressure Compound 36 (11.3 mg, 20 min) and Compound 38 (10.lmg, 25 min) were obtained together with Compound 9 (87.2 mg).
- fraction (2) is dissolved in a small amount of tetrahydrofuran, purified by preparative high-performance liquid chromatography under the same conditions as fraction (1), two fractions are collected, and each fraction is concentrated under reduced pressure.
- Compound 37 (19.8 mg, 25 min) and Compound 39 (23.2 mg, 27 min) were obtained.
- Example 20 (Compounds 40, 41)
- Radicicol (406 mg) was dissolved in N, N-dimethylformamide (6 ml), and triethylamine (57.6 mg) and thiophenol (260 mg) were added under ice-cooling, followed by stirring overnight under ice-cooling.
- Dilute hydrochloric acid was added to the reaction solution, extracted with ethyl acetate, washed with water and saturated saline in this order, dried over anhydrous magnesium sulfate, and then dried under reduced pressure.
- Zinc sulfate ( ⁇ ) heptahydrate 0.001% Zinc sulfate ( ⁇ ) heptahydrate 0.001%
- Silica gel [Silica Gel 60 (trade name, manufactured by Merck)] prepared by dissolving a portion (30 g) of a culture extract in a mixed solvent of black-mouthed form-methanol (4: 1) and moistened with n-hexane Column (1600 ml). Elution was performed sequentially with a mixed solvent of n-hexane monoethyl acetate. The fraction eluted with n-hexane-ethyl acetate (4: 1) (13 Orag), (2: 1) eluted fraction (1) (1.88 g), (2) (780 mg) and (1: 2) eluted fraction (3.56 g) were obtained.
- the fraction (1) is dissolved in a small amount of methanol, and acetonitrile-water (pH 3.5, vinegar) Preparative high-performance liquid chromatography using 4884 acid) (30:70) as the mobile phase [column: YMC-; Pack Pro C18 AS-343 (20 x 250 mm), detection UV absorption 254 nm, flow rate lOml / min] Purification, fractionation of four fractions, concentration of each fraction under reduced pressure, compound 64 (35.4 mg, 21 min), compound 72 (13.7 mg, 27 min), compound 71 (6.6 mg, 29 min), compound 65 (4. lmg, 33 min) was obtained.
- the culture extract (39.5 g) obtained in the same manner as in Example 36 was dissolved in n-hexane (300 ml ⁇ 2), and the resulting precipitate was filtered to remove the solvent.
- the obtained precipitate (8.1 g) was dissolved in a mixed solvent of chloroform-methanol (4: 1) and wetted with silica-gel form [Silica Gel 60 (trade name, manufactured by Merck)]. It was adsorbed on a column (650 ml). Elution was carried out sequentially with a mixed solvent of chloroform and methanol to obtain a fraction (318 mg) eluted with chloroform and methanol (88:12).
- the culture extract (39.5 g) obtained in the same manner as in Example 36 was dissolved in n-hexane (300 ml ⁇ 2), and the resulting precipitate was filtered to remove the solvent.
- the resulting precipitate (8.1 g) was dissolved in a mixed solvent of black form-methanol (4: 1) and wetted with black form [silica gel 60 (trade name, manufactured by Merck)]. Adsorbed to a column (650 ml). Elution was carried out sequentially with a mixed solvent of black form-methanol to obtain a fraction (1.5 g) eluted with black form-methanol (100: 0).
- Silica gel [Silica Gel 60 (trade name) prepared by dissolving the culture extract (500 g) obtained in the same manner as in Example 36 in a mixed solvent of black-mouthed form-methanol (4: 1) and moistened with black-mouthed form is used. , Manufactured by Merck)]] (6000 ml). The mixture was eluted sequentially with a mixed solvent of chloroform-methanol to obtain a fraction (57 g) eluted with chloroform-methanol (95: 5).
- the fraction (2) was purified by preparative high-performance liquid chromatography using a mobile phase of acetonitrile-water (pH 3.5, acetic acid) (45:55), and two fractions were collected. And each down pressure concentrated to give the compound 73 (38. Lmg, 10min), the compound 77 (67.2mg, 26min) was obtained.
- Example 41 Compound 67, 75
- a culture extract (500 g) obtained in the same manner as in Example 36 was dissolved in a mixed solvent of black-mouthed form-methanol (4: 1), and the silica gel [Silica Gel 60 (trade name) prepared by wetting with black-mouthed form , Manufactured by Merck)]] (6000 ml). Elution was performed sequentially with a mixed solvent of chloroform-methanol to obtain a fraction eluted with chloroform-methanol (95: 5) (57 g), and a portion (18 g) of this fraction was further dissolved in a mixed solvent of n-hexane-ethyl acetate.
- the semi-pure sample was purified by preparative thin-layer chromatography [Silic a Gel 60 F254 (trade name, manufactured by Merck), 20 cm x 20 cm, 0.5 tall] using chloroformumethanol (90:10) as a developing solvent.
- the portion having an Rf value of 0.5 was collected, extracted with ethyl acetate, and concentrated under reduced pressure to obtain compound 75 (4.3 mg).
- Table 2 shows the compounds synthesized in the above Examples, the purified compounds, and their data.
- Human dermal papilla cells were purchased from Toyobo and cultured using MEM (Invitrogen) supplemented with 12% FBS. Human follicle keratinocytes were separated from the depilated hair and cultured using KGM-2 (Sanko Junyaku) according to the method of roughing (J. Dermatol. Sci. 2, 66-70 (1991)).
- the hair papilla cells at the fifth passage and the hair follicle keratinized cells at the second passage were seeded on a 10 cm Petri dish so as to have 2 ⁇ 10 6 cells lsZwe 11, and cultured in a small scale. After removing the medium and washing the cells with PBS (1), total RNA was extracted using TRIzol reagent (Invitrogen).
- Human dermal papilla cells were purchased from Toyobo and cultured using MEM (Invitrogen) supplemented with 12% FBS.
- WNT-5A forward AATGTCTTCCAAGTTCTTCCTAGTGGC (SEQ ID NO: 8), ⁇ T-1 5A reverse: GATGTCGGAATTGATACTGGCA (SEQ ID NO: 9), GAPDH forward: ACCAC AGTCCATGCCATCAC (SEQ ID NO: 10), GAPDH reverse: TCCACCACCCTGTTGCTGTA (SEQ ID NO: 11)) 0.4 xM each, and SUPERSCRIPT One—Step RT—PCR with PLATINUM
- the CNT was repeated for 30 seconds at 72 ° C and 30 seconds at 72 ° C for 23 or 20 cycles to amplify the 0
- the reaction solution was subjected to electrophoresis using 1.5% agarose gel and stained with ethidium bromide. The result is shown in figure 2.
- Test example 3 Test for dermal papilla cell growth promotion
- Human dermal papilla cells were purchased from Toyobo and cultured using MEM (Invitrogen) supplemented with 12% FBS.
- the dermal papilla cells at the fifth passage were seeded at 1.5 ⁇ 10 4 cells lsZwell in a 96-well plate for spheroid culture, and cultured overnight.
- the medium was replaced with a compound-free medium or a medium containing Compounds 1, 2, 3, 4, 5, 7, 9, or 24, and culturing was continued for another 72 hours.
- the number of cells at the end of the culture was measured using Cell counting kit (Wako Pure Chemical Industries, Ltd.). That is, 5 hours before the end of culture, add 1Z10 amount of WST-1 reagent to the culture medium, The absorbance (OD 450 nm / 620 nm) of the medium was measured. A positive correlation was found between the cell number and the absorbance in the range of 0.25 to 4 ⁇ 10 4 cells sZwell.
- T-5A was expressed in human dermal papilla cells
- the amount of ⁇ T-5A mRNA in human dermal papilla cells was reduced by the compound according to the present invention, and that It was shown that the compound having the activity of decreasing mRNA amount has the activity of promoting the proliferation of hair papilla cells.
- Test Example 4 WNT-5A mRNA level reduction activity of compound (Table 2) (Quantitative determination of mRNA by QuantiGene method)
- Human dermal papilla cells were purchased from Toyobo and cultured using MEM (Invitrogen) supplemented with 12% FBS.
- a probe set specific to ⁇ T-5A or GAPDH was added and reacted at 53T for 20 hours.
- an amplification probe consisting of bDNA was added and reacted at 46 ° C for 1 hour.
- a labeled probe labeled with Alkaline Phosphatase was subsequently added, and reacted at 46 ° C for 1 hour.
- the substrate Lumi-Phos Plus was added, and after reacting at 46 ° C for 30 minutes, the amount of chemiluminescence was measured using WALLAC 1420ARVO SX . 03 04884
- a WNT-5A-specific probe set was designed based on the nucleotide sequence of the protein translation region of human WNT-5A mRNA. 10 probes (SEQ ID NOS: 12 to 21) as Capture Extender (CE), 31 probes (SEQ ID NOs: 22 to 52) as Label Extender (LE), and 9 probes (SEQ ID NOs: 53 to 60) as Blocker ) It was used.
- a bDNA probe set for human GAPDH (XenoTech LLC, B0960) was used.
- the mRNA level of WNT-5A and GAPDH is expressed as a relative value (%) to the control without compound.
- the compound concentration ( IC5e value) that reduces the mRNA level to 50% is calculated, and the mRNA reduction by the compound is calculated. It was used as an indicator of activity.
- Table 3 shows the effects of the compounds on the mRNA levels of WNT-5A and GAPDH.
- the values in the table are the average values of two wells. These compounds reduced WNT-5A mRNA levels in dermal papilla cells. IC 5 of the most active compound. The value was 0.12 / M. WNT- 5A IC 5 of mRNA loss. Regarding the values, no decrease was observed in the GAPDH mRNA level measured at the same time.
- Human dermal papilla cells were purchased from Toyobo and cultured using MEM (Invitrogen) supplemented with 12% FBS.
- the dermal papilla cells at the fifth passage were seeded at a density of 1.5 ⁇ 10 4 cells / well in a 96-well plate for spheroid culture, and cultured overnight.
- the medium was replaced with a compound-free medium or a compound-supplemented medium, and culturing was further performed for 72 hours.
- the number of cells at the end of the culture was measured using a Cell counting kit (Wako Pure Chemical Industries, Ltd.). That is, 5 hours before the end of the culture, 1/10 volume of the WST-1 reagent was added to the medium, and at the end of the culture, the absorbance (OD450nm / 620nm) of the medium was measured. A positive correlation was observed between the cell number and the absorbance in the cell number range of 0.25 to 4 ⁇ 10 4 cells / well.
- Table 4 shows the effect of the compound having the activity of reducing the amount of WNT-5A mRNA on the proliferation of dermal papilla cells.
- the values in the table are the average values of 6 wells for the control group and 3 weII for the compound addition group. Student's t-test was used for comparison between the control group and the compound-added group.
- Test Example 6 Decrease of ⁇ T-5A mRNA in monkey skin organ culture
- the reaction solution was subjected to electrophoresis using 1.5% agarose gel, and stained with Cyber Green I (Yukara).
- Fig. 4 shows the results.
- Test Example 7 Increase of Proliferating Cell Nuclear Antigen (PC NA) positive cells in monkey skin organ culture
- the skin of the back of a cynomolgus monkey (oss, 6 years old) was collected and divided under a stereoscopic microscope into 5 mm x 8 mm, and each skin tissue piece was added with no compound or compound 7 or 3
- the cells were cultured using Williams' Medium E (Invitrogen) containing 10 g / ml of Insulin (Sigma) and 10 ng / ml of Hydrocortisone (Krapo II).
- the skin of the back of a cynomolgus monkey (oss, 6 years old) was collected, divided under a stereoscopic microscope into 5 mm x 8 mm, and each skin tissue piece was added with no compound or with compound 7 or compound 3
- the cells were cultured using Williams' Medium E (Invitrogen) containing 10 g / ml of Insulin (Sigma) and 10 ng / ml of Hydrocortisone (Kurapo).
- the figure is a histogram showing the distribution of the hair bulb diameter. All the hair follicles contained in each skin tissue piece were classified into the groups of the hair bulb diameters shown in the figure, and the number of hair follicles classified into each group was calculated as the total number of hair follicles separated from the tissue piece. It was expressed as a relative value (%) with respect to.
- FIG. 6 shows the effect of the culture with the addition of compound 7. The average value of the bulb diameter of the hair follicles contained in the skin pieces cultured in the presence of compound 7 for 30 days was significantly higher than that of the control without compound. Looking at the distribution, the control with no compound added was 140 zm or more.
- the largest number of hair follicles had a hair bulb diameter of less than 170 im, but with the addition of Compound 7, the proportion of hair follicles having a hair bulb diameter of 170 II m or more and less than 200 ⁇ m was the largest.
- the proportion of hair follicles having a hair bulb diameter of 170 m or more increased from 57.6% in the control without compound addition to 82.4% in the compound 7 addition.
- FIG. 7 shows the effect of the culture added with compound 3.
- the average value of the bulb diameter of the hair follicles contained in the skin pieces cultured for 30 days in the presence of Compound 3 was significantly higher than that of the control containing no compound.
- the hair follicles with the diameter of the hair bulb of m or more and less than 200 m were the most frequent, but the hair bulb of 200 Um or more and less than 230 m with the addition of Compound 3
- the proportion of hair follicles having a diameter was the largest.
- the proportion of hair follicles having a hair bulb diameter of ⁇ 70 ⁇ ⁇ or more was 55.8% in the control without the compound, but increased to 74.5% in the compound 3 addition.
- Experimental Example 9 Macaca fascicularis hair growth test
- a mouthwash containing 0.3% of Compound 7 was applied to the frontal region of a macaque monkey (male, 14 years old) with alopecia symptom once a day, 5 times a week, for 6 months.
- marking was performed on the hair loss area of the frontal region with a tattoo, and enlarged photographs of the skin including the tattoo were taken before the start of the application and after the application for 6 months.
- FIG. 8 shows enlarged photographs of the skin before and after application of the lotion containing compound 7 for 6 months.
- TOT-5A is expressed in human dermal papilla cells
- the amount of TOT-5A mRNA in human dermal papilla cells is reduced by the compound according to the present invention
- WNT-5A It was shown that the compound having the activity of decreasing mRNA level has the activity of promoting the proliferation of hair papilla cells.
- the compound of the present invention can reduce the amount of WNT-5A mRNA in hair follicles in monkey skin organ culture, and can reduce PCNA in both telogen and anagen hair follicles.
- 03 04884 It was shown that the number of proliferating cells positive for staining was significantly increased, and that the diameter of the hair bulb of the hair follicle was increased.
- the compound according to the present invention was shown to have an effect of improving alopecia in a macaque monkey, a model animal for androgenetic alopecia.
- a compound that promotes the proliferation of dermal papilla cells contributes to the formation of developed dermal papilla tissue by promoting the reduced cell proliferation ability in the dermal papilla of the hair loss follicle. As a result, hair growth is promoted.
- ⁇ T-5A function inhibitors for example, ⁇ A compound having an activity to reduce the amount of T-5A mRNA or a pharmaceutically acceptable salt thereof has a hair papilla cell proliferation activity and is expressed by a novel mechanism of action. Useful as a hair preparation / hair restorer.
- the present invention provides an entirely new concept that a compound that inhibits the function of WNT-5A becomes an agent for improving or preventing alopecia, and a compound that inhibits the function of WNT-5A. Screening is useful for the development of a new hair growth agent Z.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03717623A EP1498104A4 (en) | 2002-04-17 | 2003-04-17 | TONIC PRODUCT FOR HAIR GROWTH |
US10/511,632 US20050182129A1 (en) | 2002-04-17 | 2003-04-17 | Hair growth tonic |
JP2003583359A JPWO2003086334A1 (ja) | 2002-04-17 | 2003-04-17 | 育毛剤 |
AU2003227410A AU2003227410B2 (en) | 2002-04-17 | 2003-04-17 | Hair growth tonic |
CA002482940A CA2482940A1 (en) | 2002-04-17 | 2003-04-17 | Hair growth tonic |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002115529 | 2002-04-17 | ||
JP2002-115529 | 2002-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003086334A1 true WO2003086334A1 (fr) | 2003-10-23 |
Family
ID=29243425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/004884 WO2003086334A1 (fr) | 2002-04-17 | 2003-04-17 | Produit tonique pour la pousse de cheveux |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050182129A1 (ja) |
EP (1) | EP1498104A4 (ja) |
JP (1) | JPWO2003086334A1 (ja) |
CN (1) | CN1652743A (ja) |
CA (1) | CA2482940A1 (ja) |
RU (1) | RU2312863C2 (ja) |
WO (1) | WO2003086334A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006073181A1 (ja) * | 2005-01-07 | 2006-07-13 | Noevir Co., Ltd. | 細胞賦活剤、細胞死抑制剤、および細胞死促進剤 |
JP2010501478A (ja) * | 2006-08-11 | 2010-01-21 | ユニベルシテ・ドウ・ストラスブール | キナーゼおよびhsp90の阻害剤として有用な大環状化合物 |
JP2015110624A (ja) * | 2008-01-15 | 2015-06-18 | ユニベルシテ・ドウ・ストラスブール | 治療薬として有用なレゾルシン酸ラクトンの合成 |
JP2020531581A (ja) * | 2017-08-20 | 2020-11-05 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアThe Regents of the University of California | 緑内障を治療するためのWnt5aの調節 |
WO2022092284A1 (ja) | 2020-10-30 | 2022-05-05 | 日産化学株式会社 | 脂質ペプチドとショ糖エステルを含む組成物 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070120559A (ko) * | 2005-03-29 | 2007-12-24 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 새로운 모낭 생성 방법, 탈모 치료 방법 및 체모 제거 방법 |
US7815903B2 (en) * | 2005-06-22 | 2010-10-19 | Aligarh Muslim University | Process for commercial production of biopesticides |
US7601852B2 (en) * | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
US20110190237A1 (en) * | 2008-01-15 | 2011-08-04 | Nexgenix Pharmaceuticals | Macrocyclic Prodrug Compounds Useful as Therapeutics |
AU2009217315B2 (en) * | 2008-02-21 | 2014-09-04 | Oncosynergy, Inc. | Macrocyclic prodrug compounds useful as therapeutics |
EP2483259A1 (en) * | 2009-09-28 | 2012-08-08 | Universite De Strasbourg | Irreversible inhibitors useful for the treatment of kinase-related pathologies |
US8846723B2 (en) | 2010-07-29 | 2014-09-30 | Eastman Chemical Company | Esters of O-substituted hydroxy carboxylic acids and preparations thereof |
US8613940B2 (en) | 2010-09-03 | 2013-12-24 | Eastman Chemical Company | Carbonate derivatives as skin care |
US8329938B2 (en) | 2011-02-21 | 2012-12-11 | Eastman Chemical Company | Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol |
CN102265877B (zh) * | 2011-07-22 | 2013-01-23 | 中国科学院华南植物园 | β-雷琐酸大环内酯在有害螺类防治中的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687982A (en) * | 1971-03-09 | 1972-08-29 | Commercial Solvents Corp | Separation of mixed diastereoisomers of zearalanol |
EP0606044A1 (en) * | 1992-12-04 | 1994-07-13 | Sandoz Ltd. | Lactones compounds useful as pharmaceuticals |
JPH09202781A (ja) * | 1996-01-25 | 1997-08-05 | Sankyo Co Ltd | ラディシコール誘導体 |
WO2001074164A1 (en) * | 2000-03-31 | 2001-10-11 | The General Hospital Corporation | Methods of modulating hair growth |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3239345A (en) * | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
FR96016E (fr) * | 1966-06-29 | 1972-05-19 | Commercial Solvents Corp | Composé utilisable comme supplément alimentaire pour les animaux. |
US5795910A (en) * | 1994-10-28 | 1998-08-18 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
ATE328888T1 (de) * | 2000-08-25 | 2006-06-15 | Sloan Kettering Inst Cancer | Radicicol und monocillin und ihre analogen und ihre anwendungen |
-
2003
- 2003-04-17 WO PCT/JP2003/004884 patent/WO2003086334A1/ja active Application Filing
- 2003-04-17 US US10/511,632 patent/US20050182129A1/en not_active Abandoned
- 2003-04-17 CA CA002482940A patent/CA2482940A1/en not_active Abandoned
- 2003-04-17 RU RU2004133555/04A patent/RU2312863C2/ru not_active IP Right Cessation
- 2003-04-17 CN CNA038113252A patent/CN1652743A/zh active Pending
- 2003-04-17 JP JP2003583359A patent/JPWO2003086334A1/ja active Pending
- 2003-04-17 EP EP03717623A patent/EP1498104A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687982A (en) * | 1971-03-09 | 1972-08-29 | Commercial Solvents Corp | Separation of mixed diastereoisomers of zearalanol |
EP0606044A1 (en) * | 1992-12-04 | 1994-07-13 | Sandoz Ltd. | Lactones compounds useful as pharmaceuticals |
JPH09202781A (ja) * | 1996-01-25 | 1997-08-05 | Sankyo Co Ltd | ラディシコール誘導体 |
WO2001074164A1 (en) * | 2000-03-31 | 2001-10-11 | The General Hospital Corporation | Methods of modulating hair growth |
Non-Patent Citations (1)
Title |
---|
See also references of EP1498104A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006073181A1 (ja) * | 2005-01-07 | 2006-07-13 | Noevir Co., Ltd. | 細胞賦活剤、細胞死抑制剤、および細胞死促進剤 |
JP2010501478A (ja) * | 2006-08-11 | 2010-01-21 | ユニベルシテ・ドウ・ストラスブール | キナーゼおよびhsp90の阻害剤として有用な大環状化合物 |
JP2015110624A (ja) * | 2008-01-15 | 2015-06-18 | ユニベルシテ・ドウ・ストラスブール | 治療薬として有用なレゾルシン酸ラクトンの合成 |
JP2020531581A (ja) * | 2017-08-20 | 2020-11-05 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアThe Regents of the University of California | 緑内障を治療するためのWnt5aの調節 |
JP7299889B2 (ja) | 2017-08-20 | 2023-06-28 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア | 緑内障を治療するためのWnt5aの調節 |
WO2022092284A1 (ja) | 2020-10-30 | 2022-05-05 | 日産化学株式会社 | 脂質ペプチドとショ糖エステルを含む組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN1652743A (zh) | 2005-08-10 |
AU2003227410A1 (en) | 2003-10-27 |
CA2482940A1 (en) | 2003-10-23 |
RU2312863C2 (ru) | 2007-12-20 |
EP1498104A1 (en) | 2005-01-19 |
EP1498104A4 (en) | 2006-05-03 |
RU2004133555A (ru) | 2005-06-10 |
US20050182129A1 (en) | 2005-08-18 |
JPWO2003086334A1 (ja) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003086334A1 (fr) | Produit tonique pour la pousse de cheveux | |
JPH08175990A (ja) | Pi3キナーゼ阻害剤とその製造法 | |
JP2001516694A (ja) | プロテインキナーゼ、gプロテイン及びポリメラーゼのプリン阻害剤 | |
JP2007291075A (ja) | 新規化合物ステレニン及びその製造方法 | |
US8980587B2 (en) | Process for producing reveromycin A or a synthetic intermediate thereof, process for producing compounds containing a spiroketal ring and novel antineoplastics, fungicides and therapeutic agents for bone disorders | |
JPH1045747A (ja) | アンチマイシンa系化合物の混合物 | |
TW202018077A (zh) | 桑黃屬桑黃株及其產物、萃取物及應用 | |
KR101499266B1 (ko) | 6-알콕시알킬 에스트라디올 유도체 및 사용법 | |
US8952140B2 (en) | Compound amycolose derivative, method for producing the same, and use of the same | |
JP7057945B2 (ja) | 上皮間葉転換誘導細胞阻害剤 | |
JPH09506627A (ja) | Trichoderma virensから製造した新規なカリウムチャンネルアゴニスト | |
KR20010022050A (ko) | 제암제 | |
JP2001031564A (ja) | テロメレース阻害剤 | |
JP2003503412A (ja) | 海洋放線菌に由来する新規のインドロカルバゾールアルカロイド | |
JP2015013825A (ja) | 新規化合物キノフラシン類、その製造方法、及びその用途、並びに新規微生物 | |
AU2021104214A4 (en) | A process for developing lysophosphatidic acid receptor 6 (lpar6) antagonists that inhibit hepatocellular carcinoma growth | |
JP4604556B2 (ja) | フィブロネクチン産生促進剤 | |
US20030216354A1 (en) | Decalactones, method for making, and pharmaceuticals there from | |
CN1390218A (zh) | 新的活性海洋生物碱类物质 | |
KR20150125388A (ko) | LasiRNA를 유효성분으로 포함하는 피부 미백용 조성물 | |
JP3733163B2 (ja) | 化合物tan−2177、その製造法および用途 | |
JP4629993B2 (ja) | ピラゾロン誘導体及びテロメラーゼ阻害剤 | |
JPH0967360A (ja) | 癌遺伝子機能抑制剤 | |
CN1830960B (zh) | 10-苯基氢化异吲哚酮类化合物及其制备方法和用途 | |
CN117942324A (zh) | 酚类化合物在抑制细胞铁死亡和防治铁死亡相关疾病中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2482940 Country of ref document: CA Ref document number: 2003583359 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10511632 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003227410 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003717623 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004133555 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038113252 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003717623 Country of ref document: EP |